Gene Therapy Offers Hope for Spinal Cord Injury Spasticity

Muscle spasticity, characterized by stiffness and involuntary spasms, significantly impacts individuals with spinal cord injuries. A new gene therapy, developed using an inactive virus to deliver genes for GABA neurotransmitter production, is showing promising results in preclinical studies. This approach aims to rebalance overactive nerve circuits by restoring natural inhibitory signals in the injured spinal cord.

In animal models, the gene therapy led to a notable decrease in muscle spasticity and improved regulation of nerve activity. Researchers observed reduced muscle stiffness and spasms, alongside a partial restoration of normal spinal reflexes. Importantly, extensive safety evaluations in rats, monitored for up to 4.5 years, revealed no significant negative effects, with the viral delivery system remaining localized to the spinal cord.

This innovative therapy offers the potential for long-lasting relief from a single administration, a significant advantage over current treatments requiring repeated interventions. While still in the preclinical stages, the findings provide hope for a new therapeutic option that addresses the underlying causes of spasticity, potentially enhancing mobility and quality of life for those affected by spinal cord injuries.